135 related articles for article (PubMed ID: 22957932)
1. Dry eye syndrome in aromatase inhibitor users.
Turaka K; Nottage JM; Hammersmith KM; Nagra PK; Rapuano CJ
Clin Exp Ophthalmol; 2013 Apr; 41(3):239-43. PubMed ID: 22957932
[TBL] [Abstract][Full Text] [Related]
2. Ocular Surface Disease in Breast Cancer Patients Using Aromatase Inhibitors.
Chatziralli I; Sergentanis T; Zagouri F; Chrysikos D; Ladas I; Zografos GC; Moschos M
Breast J; 2016 Sep; 22(5):561-3. PubMed ID: 27296769
[TBL] [Abstract][Full Text] [Related]
3. Dry eyes and AIs: If you don't ask you won't find out.
Inglis H; Boyle FM; Friedlander ML; Watson SL
Breast; 2015 Dec; 24(6):694-8. PubMed ID: 26422124
[TBL] [Abstract][Full Text] [Related]
4. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
Lycette JL; Luoh SW; Beer TM; Deloughery TG
Breast Cancer Res Treat; 2006 Oct; 99(3):249-55. PubMed ID: 16752073
[TBL] [Abstract][Full Text] [Related]
5. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM
Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
[TBL] [Abstract][Full Text] [Related]
6. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Nishiyama K; Inaji H
Anticancer Res; 2009 Nov; 29(11):4791-4. PubMed ID: 20032437
[TBL] [Abstract][Full Text] [Related]
8. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
[TBL] [Abstract][Full Text] [Related]
9. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
10. Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Gibson K; O'Bryant CL
J Oncol Pharm Pract; 2008 Sep; 14(3):139-45. PubMed ID: 18719068
[TBL] [Abstract][Full Text] [Related]
11. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
12. No pain, no gain: a fallacy so far.
Gradishar WJ
J Clin Oncol; 2015 Jan; 33(3):235-7. PubMed ID: 25512459
[No Abstract] [Full Text] [Related]
13. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Winters L; Habin K; Gallagher J
Clin J Oncol Nurs; 2007 Jun; 11(3):433-9. PubMed ID: 17623627
[TBL] [Abstract][Full Text] [Related]
15. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ;
Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Kyvernitakis I; Ziller V; Hars O; Bauer M; Kalder M; Hadji P
Climacteric; 2014 Jun; 17(3):252-9. PubMed ID: 23805799
[TBL] [Abstract][Full Text] [Related]
17. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Bundred NJ; Campbell ID; Davidson N; DeBoer RH; Eidtmann H; Monnier A; Neven P; von Minckwitz G; Miller JC; Schenk NL; Coleman RE
Cancer; 2008 Mar; 112(5):1001-10. PubMed ID: 18205185
[TBL] [Abstract][Full Text] [Related]
18. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
19. Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Tang SC
Oncology; 2010; 79(1-2):13-26. PubMed ID: 21051913
[TBL] [Abstract][Full Text] [Related]
20. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
Schilder CM; Seynaeve C; Beex LV; Boogerd W; Linn SC; Gundy CM; Huizenga HM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
J Clin Oncol; 2010 Mar; 28(8):1294-300. PubMed ID: 20142601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
